Details for Patent: 8,906,410
Which drugs does patent 8,906,410 protect, and when does it expire?
Patent 8,906,410 protects RAYALDEE and is included in one NDA.
This patent has twenty-nine patent family members in thirteen countries.
Summary for Patent: 8,906,410
| Title: | Oral dosage form of 25-hydroxyvitamin D |
| Abstract: | Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3. |
| Inventor(s): | Charles W. Bishop, Keith H. Crawford, Eric J. Messner |
| Assignee: | Opko Health Inc , Opko Renal LLC |
| Application Number: | US13/848,982 |
|
Patent Claim Types: see list of patent claims | Formulation; Compound; Dosage form; |
Drugs Protected by US Patent 8,906,410
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eirgen | RAYALDEE | calcifediol | CAPSULE, EXTENDED RELEASE;ORAL | 208010-001 | Jun 17, 2016 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,906,410
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2640094 | ⤷ Start Trial | |||
| Canada | 2882048 | ⤷ Start Trial | |||
| Cyprus | 1118017 | ⤷ Start Trial | |||
| Cyprus | 1125077 | ⤷ Start Trial | |||
| Denmark | 1993559 | ⤷ Start Trial | |||
| Denmark | 3095447 | ⤷ Start Trial | |||
| European Patent Office | 1993559 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
